V.F. Tapson

Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease

Reda E. Girgis, Adaani Frost, N.S. Hill et al. · Annals of the Rheumatic Diseases · 2007 · 98 citations · Full text

Effect of Selexipag on Morbidity/Mortality in Pulmonary Arterial Hypertension: Results of the GRIPHON Study

Nazzareno Galiè, Richard N. Channick, K. Chin et al. · The Journal of Heart and Lung Transplantation · 2015 · 15 citations

Thrombosis, Hypertension, Pulmonary Arterial Hypertension +11

A consensus conference on complex biologics and low molecular weight heparins.

Evi Kalodiki, Jawed Fareed, V.F. Tapson et al. · PubMed · 2010 · 11 citations

Consensus Conference, Hepatology, Liver Physiology +8

Sustained Plasma Concentrations of Treprostinil Following Chronic Dosing in Patients with Pulmonary Arterial Hypertension (PAH).

R.J. White, Roblee P. Allen, Ferràn Torres et al. · 2009 · 10 citations

Plasma Concentrations, Therapeutic Drug Monitoring, Hypertension +10

Results of the FREEDOM–C Study: A Pivotal Study of Oral Treprostinil Used Adjunctively with an ERA and/or PDE5-Inhibitor for the Treatment of PAH.

V.F. Tapson, Fernando Torres, F. Kermeen et al. · 2009 · 10 citations

Medicine, Clinical Pharmacology, Pivotal Study +5